Effect of peptide YY on gastric, pancreatic, and biliary function in humans.
The effect of peptide YY (PYY) on gastric and pancreatico-biliary secretion was studied in humans. Peptide YY was infused into groups of 6 healthy volunteers at doses of 0.59, 0.20, and 0.064 pmol X kg-1 X min-1. The two higher doses caused a significant suppression of gastric acid and pepsin output during background stimulation with pentagastrin. The middle dose of PYY (0.20 pmol X kg-1 X min-1) that increased plasma PYY levels by 27 +/- 2 pM caused a 90% +/- 18% (mean +/- SEM; p less than 0.001) reduction in the incremental gastric volume response to pentagastrin. Similarly this dose of PYY caused a substantial inhibition of the acid (77% +/- 14%; p less than 0.005) and pepsin (96% +/- 22%; p less than 0.01) response to pentagastrin; in 2 subjects, pepsin output fell to below basal levels. In contrast, the highest dose of PYY (0.62 pmol X kg-1 X min-1) had no significant influence on duodenal juice volume, output of bicarbonate, trypsin, or bilirubin during low dose stimulation with secretin (0.25 pmol X kg-1 X min-1) and cholecystokinin-8 (0.15 pmol X kg-1 X min-1). Thus PYY concentrations in the circulation similar to those seen after the ingestion of food cause a marked reduction in gastric secretion. This peptide should therefore be considered as one of the possible candidates for the classical enterogastrone.
D000293:Adolescent; D000328:Adult; D001646:Bile / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004386:Duodenum; D005215:Fasting; D005750:Gastric Juice / Q000032:analysis; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D005768:Gastrointestinal Hormones / Q000494:pharmacology*; D006801:Humans; D007419:Intestinal Secretions / Q000032:analysis; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism; D019894:Peptide YY; D010455:Peptides / Q000097:blood / Q000494:pharmacology*
D005768:Gastrointestinal Hormones; D010455:Peptides; D019894:Peptide YY